Lashan Peiris

#Oncoplastic #breastcancer surgeon from Winchester, UK - now in #Edmonton, #Alberta specialising in #BreastReconstruction and Oncoplastic Breast Conservation

[Pierre Blanchard, MD @PBlanchardMD]

10y results of FAST FORWARD (adjuvant #breastcancer RT) trial presented at #ESTRO25 by AM Brunt.

Compared to 40Gy/15, 26Gy/5:
1. Non inf for IBR (even superior?)
2. Similar recurrence free interval, breast cancer interval, OS
3. No diff in PRO or toxicity

Clearly 26/5 SOC for

[Cam @Cweitz99]

This angle of the McDavid goal is art

[JAMA Oncology @JAMAOnc]

Most viewed in the last 7 days from @JAMAOnc:

Do young breast cancer survivors have a high risk of developing a second primary breast cancer?

https://t.co/skty5R4T8c

[Lashan Peiris @Oncoplasticsurg]

https://t.co/57oZu7t6e1 Come join our great team!

[Lashan Peiris @Oncoplasticsurg]

@AnnSurgOncol @therealmiral @SocSurgOnc Interesting data, but a 44% complication rate for Oncoplastic surgery seems outrageously high. Also why delay OPBS 10-14d post-BCS. Why not do it all at once?Multiple studies- including our own- show these can be done by a single team all at once, with a complication rate of <9%

[Steven D Wexner MD, PhD @SWexner]

Axillary management in breast cancer after neoadjuvant chemotherapy in the modern era: @AmCollSurgeons @AmColSurgCancer A national cancer database analysis in @SurgJournal by @AliciaHeelan @UCincySurg @UCincyMedicine https://t.co/ldkJbrJr6p

[Lashan Peiris @Oncoplasticsurg]

@DrTedJames @RICKLIN4TH Agree - ALND is overtreatment in these patients who convert to ypN0. This approach is the Z1071 subgroup analysis of clipping biopsied nodes pre-NAC and - if normal nodes identified on post-NAC axillary US - then tAD can be performed demonstrating a low FNR of <5%.

[Lashan Peiris @Oncoplasticsurg]

@GlassmanDS @MelissaLHTan Choosing Wisely contingent on patients taking full course of endocrine treatment. Data suggests only 60% of patients compliant with endo. Also in the SLNB arm of SOUND 14% were pN1. Omitting SLNB means this group loses out on valuable locoregional RT / endo and ⬆️LR failure

[Lashan Peiris @Oncoplasticsurg]

Very humbled and proud to be the new lead for the Comprehensive Breast Care Program in #Edmonton. The CBCP is a strong driver for research, innovation and patient-centred care. I look forward to helping it grow and serve our patients diagnosed with #breastcancer #Yeg @CovenantCA

[Society of Surgical Oncology @SocSurgOnc]

As breast fellowship matches are celebrated today, review this article from @AnnSurgOncol PUBLISHED: Comparing Methods for #TargetedAxillaryDissection in #BreastCancer Patients: A Nationwide, Retrospective Study.
https://t.co/AnmM0yWr7Q

[Judy Boughey @DrJudyBoughey]

Breast conservation is an appropriate option for women with 2-3 foci of breast cancer in their breast. Primary endpoint of Alliance Z11102 clinical trial reported in JCO. ⁦@ALLIANCE_org⁩ @MayoCancerCare⁩ ⁦@MayoClinicSurg⁩ https://t.co/BL34Jq5TyA

[Lashan Peiris @Oncoplasticsurg]

@alilyroberts @OntariosDoctors @CDNMinHealth This is great news. Keep us posted, and we’ll see if the rest of the country can follow suit!

[Minas Chrysopoulo MD FACS @drchrysopoulo]

The latest The PRMA Breast Cancer News! https://t.co/o190AzNsR5 Thanks to @bccww @ASJrnl @drroykim #plasticsurgery #prsjournal

[BJS @BJSurgery]

In the BJS December issue: Axillary lymph node dissection can be omitted in patients with limited clinically node-positive breast cancer https://t.co/BkGKcV0pbW @bplwijn @des_winter @ksoreide @MalinASund @evanscolorectal @nfmkok @paulo_sutt @robhinchliffe1 @young_bjs

[Shiela Appavoo MD @ShielaAppavoo]

And here is the link to the webinar. Thanks again to CSBI and our volunteer speakers. #BCAM #BreastCancerAwarenessMonth

https://t.co/P3UkPbu34o

[Shiela Appavoo MD @ShielaAppavoo]

@Conjure_pup @ThanksCancer Thanks for asking. I’m not a surgeon, but you can hear @Oncoplasticsurg, Dr Lashan Peiris, talk about modern Breast surgery options in this free @CanadaSBI webinar. #breastcancer

Lots of great questions answered at the end of his session, too!

[Lashan Peiris @Oncoplasticsurg]

@shivanishah_ @AnnSurgOncol @JoshuaBloomMD @Chatterjeeonco1 @drbernardlee @bidmcharvardprs @harvardmed Strong work. Congrats 👏👏👏

[Anushka Chaudhry @askanushka]

The first of its kind, inspiring, innovative and inclusive Breast cancer meeting. Great debate, minds and collaborative thoughts all in one space. Makes me excited to be a breast surgeon. #TBCC2022 @endomag

[Mathew Stephens @MathewStephens]

Excited to be heading to the inaugural Transatlantic Breast Cancer Collaborative - 70 of the best breast surgeons from across the world in one place to discuss, debate, and define the future of breast cancer treatment.

#TBCC2022 #DiscussDebateDefine #BreastCancer #Magteam

[Lashan Peiris @Oncoplasticsurg]

@Abhishe19365903 @AnnSurgOncol Sadly - although interesting - I feel that this is the main drawback of these 2 cohort studies. There will always be a selection bias with earlier stage cancers over-represented in the BCT group. Only way to know for sure is with prospective RCTs emulating those of the 1990s.